Neuropsychiatric SLE: From animal model to human

R. Pikman, Shaye Kivity, Y. Levy, M. T. Arango, Joab Chapman, H. Yonath, Yehuda Shoenfeld, S. G. Gofrit

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed "targeted biological medication" is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease.

Original languageEnglish (US)
Pages (from-to)470-477
Number of pages8
JournalLupus
Volume26
Issue number5
DOIs
StatePublished - Apr 1 2017

Fingerprint

Animal Models
Pharmaceutical Preparations
Poisons
Research
Therapeutics
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Pikman, R., Kivity, S., Levy, Y., Arango, M. T., Chapman, J., Yonath, H., ... Gofrit, S. G. (2017). Neuropsychiatric SLE: From animal model to human. Lupus, 26(5), 470-477. https://doi.org/10.1177/0961203317694261
Pikman, R. ; Kivity, Shaye ; Levy, Y. ; Arango, M. T. ; Chapman, Joab ; Yonath, H. ; Shoenfeld, Yehuda ; Gofrit, S. G. / Neuropsychiatric SLE : From animal model to human. In: Lupus. 2017 ; Vol. 26, No. 5. pp. 470-477.
@article{0c19a7fe47b34bc1bd10d031bcc640b1,
title = "Neuropsychiatric SLE: From animal model to human",
abstract = "Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed {"}targeted biological medication{"} is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease.",
author = "R. Pikman and Shaye Kivity and Y. Levy and Arango, {M. T.} and Joab Chapman and H. Yonath and Yehuda Shoenfeld and Gofrit, {S. G.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1177/0961203317694261",
language = "English (US)",
volume = "26",
pages = "470--477",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "5",

}

Pikman, R, Kivity, S, Levy, Y, Arango, MT, Chapman, J, Yonath, H, Shoenfeld, Y & Gofrit, SG 2017, 'Neuropsychiatric SLE: From animal model to human', Lupus, vol. 26, no. 5, pp. 470-477. https://doi.org/10.1177/0961203317694261

Neuropsychiatric SLE : From animal model to human. / Pikman, R.; Kivity, Shaye; Levy, Y.; Arango, M. T.; Chapman, Joab; Yonath, H.; Shoenfeld, Yehuda; Gofrit, S. G.

In: Lupus, Vol. 26, No. 5, 01.04.2017, p. 470-477.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuropsychiatric SLE

T2 - From animal model to human

AU - Pikman, R.

AU - Kivity, Shaye

AU - Levy, Y.

AU - Arango, M. T.

AU - Chapman, Joab

AU - Yonath, H.

AU - Shoenfeld, Yehuda

AU - Gofrit, S. G.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed "targeted biological medication" is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease.

AB - Animal models are a key element in disease research and treatment. In the field of neuropsychiatric lupus research, inbred, transgenic and disease-induced mice provide an opportunity to study the pathogenic routes of this multifactorial illness. In addition to achieving a better understanding of the immune mechanisms underlying the disease onset, supplementary metabolic and endocrine influences have been discovered and investigated. The ever-expanding knowledge about the pathologic events that occur at disease inception enables us to explore new drugs and therapeutic approaches further and to test them using the same animal models. Discovery of the molecular targets that constitute the pathogenic basis of the disease along with scientific advancements allow us to target these molecules with monoclonal antibodies and other specific approaches directly. This novel therapy, termed "targeted biological medication" is a promising endeavor towards producing drugs that are more effective and less toxic. Further work to discover additional molecular targets in lupus' pathogenic mechanism and to produce drugs that neutralize their activity is needed to provide patients with safe and efficient methods of controlling and treating the disease.

UR - http://www.scopus.com/inward/record.url?scp=85018348850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018348850&partnerID=8YFLogxK

U2 - 10.1177/0961203317694261

DO - 10.1177/0961203317694261

M3 - Article

C2 - 28394237

AN - SCOPUS:85018348850

VL - 26

SP - 470

EP - 477

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -

Pikman R, Kivity S, Levy Y, Arango MT, Chapman J, Yonath H et al. Neuropsychiatric SLE: From animal model to human. Lupus. 2017 Apr 1;26(5):470-477. https://doi.org/10.1177/0961203317694261